Hepatitis C Co-Infection

Hepatitis C is a serious and underreported global health problem. According to the World Health Organization (WHO), about 71 million people worldwide are infected with hepatitis C virus (HCV) infection and 399,000 die of HCV-related causes each year. Approximately 2.3 million of the estimated 36.7 million people living with HIV globally have current or previous HCV infection, and liver diseases are a major cause of illness and death among people living with HIV.

The newer direct-acting antivirals (DAAs) can cure more than 95% of people with HCV infection and treatment is shorter and safer compared with older therapies. But despite the existence of generic versions of these medicines, DAAs remain difficult to access for many who need them.¹

amfAR’s TREAT Asia program advocates for HCV treatment access and trains physicians in the care of patients with HIV/HCV coinfection.

¹World Health Organization. Hepatitis C factsheet. Updated July 2018  

Treatment Snapshots

Velpatasvir + Sofosbuvir (September 2017)

Ledipasvir + Sofosbuvir (March 2016)  

Daclatasvir (February 2016)

Sofosbuvir (August 2015)

Fact Sheets

Fact Sheet: WHO Guidelines for the Screening, Care, and Treatment of Persons with Hepatitis C Infection (November 2018)
Available in English, Mandarin, Indonesia Bahasa, Malay, Thai, and Vietnamese.

Fact Sheet on WHO Guidelines for the Screening, Care, and Treatment of Persons with Hepatitis C Infection (June 2016)

Fact Sheet: WHO Guidelines for the Screening, Care, and Treatment of Persons with Hepatitis C Infection (August 2014)

Policy and Issue Briefs

Hepatitis C: Policy Recommendations for Addressing a Growing Epidemic (June 2018)

Hepatitis C and Drug Pricing: The Need for a Better Balance (February 2015)

Policy Brief: Hepatitis C and HIV – Addressing the Dual Epidemic (February 2014)  

Co-infection Informational Video

Dr. Nicolas Durier speaks about TREAT Asia’s hepatitis C treatment study (July 2015)

Patient Materials

Animated videos: Hepatitis C Infection and Treatment (June 2014)

Flipcharts: Hepatitis C Infection and Treatment (October 2013)

Patient Booklets: Hepatitis C Infection and Treatment (November 2013)

 Flyers (October 2013)  

Patient Treatment Plan Booklets (October 2013)

Articles on Hepatitis C

Enhancing Access to Newer HIV and Hepatitis C Medications in Asia (November 6, 2018)

Hepatitis C Diagnosis and Treatment Access: Progress and Challenges (September 17, 2018)

The 2018 International Liver Congress and Civil Society’s Role in Tackling Hepatitis Worldwide (May 23, 2018)

A Partnership to Build Hepatitis C Diagnosis and Treatment Access in Asia (January 2018)

TREAT Asia, Civil Society Groups, and WHO Coordinate Efforts to Attack Viral Hepatitis (January 2018)

When Drugs Cost as Much as Diamonds (May 2017)

Improving Hepatitis C Care in At-Risk Populations (September 2016)

TREAT Asia Pushes for Expanded Access to Hepatitis C Treatments (September 2016)

TREAT Asia Conducts Physician Training on HIV and Hepatitis C
Co-infection Treatment (July 2016)

CoNE, India, Is Selected in Global Hepatitis Innovation Testing Contest (May 2016)

Addressing the Challenges to HIV/Hepatitis C Treatment Access (March 2016)

Indian Generic Companies Begin Production on Two New Hepatitis C Treatments (January 2016)

New Recommendations for Treating Hepatitis C Among People Who Inject Drugs (November 2015)

How Activists Are Driving Down the Cost of Hepatitis C Treatment in Asia (November 2015)

How the WHO Is Taking the Lead in Combating Global Hepatitis (September 2015)

Treating Hepatitis C Among People Who Use Drugs (January 2015)

TREAT Asia Launches a New Hepatitis C Training Series for Clinicians (September 2014)

A Way Forward for Hepatitis C Treatment Access in Asia (July 2014)

TREAT Asia Launches a New Hepatitis C Education Campaign and Screening and Treatment Study (February 2014)